B
APLS

Bailard’s Apellis Pharmaceuticals APLS Stock Holding History

Bailard’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,800
Closed -$430K – 704
2021
Q2 		$430K Sell
6,800
-6,000
-47% -$310K 0.01% 433
2021
Q1 		$549K Sell
12,800
-1,200
-9% -$56.8K 0.02% 373
2020
Q4 		$801K Sell
14,000
-2,900
-17% -$123K 0.04% 241
2020
Q3 		$510K Hold
16,900
– – 0.03% 280
2020
Q2 		$552K Buy
16,900
+5,000
+42% +$161K 0.03% 258
2020
Q1 		$319K Buy
11,900
+900
+8% +$32K 0.02% 305
2019
Q4 		$337K Sell
11,000
-4,000
-27% -$111K 0.02% 384
2019
Q3 		$361K Hold
15,000
– – 0.02% 360
2019
Q2 		$380K Buy
15,000
+2,000
+15% +$40.7K 0.02% 355
2019
Q1 		$254K Buy
+13,000
New +$204K 0.02% 450

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bailard's APLS Position: Q3 2021 in Review

Bailard sold out of Apellis Pharmaceuticals (APLS) in Q3 2021, closing a stake of 6,800 shares — an estimated $430K sold.

Bailard first reported a position in APLS in Q1 2019 and held it in 10 quarters. The position peaked at $801K in Q4 2020. 180 funds tracked by Wall St. Rank hold APLS as of Q3 2021.

  • Bailard reported no remaining Apellis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bailard sold 6,800 Apellis Pharmaceuticals shares in Q3 2021, an estimated $430K.
  • Bailard first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 10 quarters.
  • Bailard's Apellis Pharmaceuticals position peaked at $801K in Q4 2020.
  • 180 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2021.

Based on Bailard's 13F filing for Q3 2021, filed 15 Nov 2021.